Overview
This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).
Eligibility
Inclusion Criteria:
- Has completed an enlicitide decanoate (also known as enlictide and MK-0616) parent study [MK-0616-013 (NCT05952856), MK-0616-017 (NCT05952869), and MK-0616-018 (NCT06450366)] per protocol (including the final assessments/procedures of their parent study)
- Had an overall study intervention compliance ≥80% while participating in their parent study
Exclusion Criteria:
- Has discontinued study intervention in their parent study
- Has an ongoing serious adverse event considered related to study intervention by the investigator in the parent study
- Is planning to begin treatment with a nonstudy protein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) while enrolled in the study
- Is currently participating in an interventional clinical study other than an enlicitide decanoate parent study